{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T04:21:12Z","timestamp":1794543672286,"version":"4.9.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":60,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Military Medical Priority Discipline Development Program (General Surgery) of the People's Liberation Army"},{"name":"Artificial Intelligence+ Medical Research Project of the Army Medical Center"},{"DOI":"10.13039\/501100005230","name":"Chongqing Natural Science Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005230","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"DOI":"10.1186\/s13058-026-02307-7","type":"journal-article","created":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T11:48:14Z","timestamp":1779536894000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["ZNF831 suppresses triple-negative breast cancer progression through NLRP3-associated pyroptotic signaling and M1-like macrophage phenotypic remodeling"],"prefix":"10.1186","volume":"28","author":[{"given":"Qingqing","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wantao","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangwu","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yupei","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangxue","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shimeng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,23]]},"reference":[{"key":"2307_CR1","doi-asserted-by":"publisher","first-page":"477","DOI":"10.3322\/caac.21863","volume":"74","author":"AN Giaquinto","year":"2024","unstructured":"Giaquinto AN, Sung H, Newman LA, Freedman RA, Smith RA, Star J, et al. Breast cancer statistics 2024. CA Cancer J Clin. 2024;74:477\u201395. https:\/\/doi.org\/10.3322\/caac.21863.","journal-title":"CA Cancer J Clin"},{"key":"2307_CR2","doi-asserted-by":"publisher","first-page":"3867","DOI":"10.1200\/JCO.22.02864","volume":"41","author":"AC Wolff","year":"2023","unstructured":"Wolff AC, Somerfield MR, Dowsett M, Hammond MEH, Hayes DF, McShane LM, et al. Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-college of American pathologists guideline update. J Clin Oncol: Off J Am Soc Clin Oncol. 2023;41:3867\u201372. https:\/\/doi.org\/10.1200\/JCO.22.02864.","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"2307_CR3","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa2202809","volume":"387","author":"J Cortes","year":"2022","unstructured":"Cortes J, Rugo HS, Cescon DW, Im S-A, Yusof MM, Gallardo C, et al. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N Engl J Med. 2022;387:217\u201326. https:\/\/doi.org\/10.1056\/NEJMoa2202809.","journal-title":"N Engl J Med"},{"key":"2307_CR4","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid P, Cortes J, Pusztai L, McArthur H, K\u00fcmmel S, Bergh J, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382:810\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1910549.","journal-title":"N Engl J Med"},{"key":"2307_CR5","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s40364-024-00714-6","volume":"12","author":"Z Guo","year":"2024","unstructured":"Guo Z, Zhu Z, Lin X, Wang S, Wen Y, Wang L, et al. Tumor microenvironment and immunotherapy for triple-negative breast cancer. Biomark Res. 2024;12:166. https:\/\/doi.org\/10.1186\/s40364-024-00714-6.","journal-title":"Biomark Res"},{"key":"2307_CR6","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.1016\/j.ymthe.2025.03.024","volume":"33","author":"R Jiang","year":"2025","unstructured":"Jiang R, Yang L, Liu X, Xu Y, Han L, Chen Y, et al. Genetically engineered macrophages reverse the immunosuppressive tumor microenvironment and improve immunotherapeutic efficacy in TNBC. Mol Ther. 2025;33:3339\u201359. https:\/\/doi.org\/10.1016\/j.ymthe.2025.03.024.","journal-title":"Mol Ther"},{"key":"2307_CR7","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41523-025-00799-8","volume":"11","author":"A Sharma","year":"2025","unstructured":"Sharma A, Sudan SK, Vikramdeo KS, Khan MA, Tahir M, Carter JE, et al. Subtype- and race-specific variations in the immune landscape of breast cancer: therapeutic implications. npj Breast Cancer. 2025;11:78. https:\/\/doi.org\/10.1038\/s41523-025-00799-8.","journal-title":"npj Breast Cancer"},{"key":"2307_CR8","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41392-025-02325-5","volume":"10","author":"J Xu","year":"2025","unstructured":"Xu J, Ding L, Mei J, Hu Y, Kong X, Dai S, et al. Dual roles and therapeutic targeting of tumor-associated macrophages in tumor microenvironments. Signal Transduct Target Ther. 2025;10:268. https:\/\/doi.org\/10.1038\/s41392-025-02325-5.","journal-title":"Signal Transduct Target Ther"},{"key":"2307_CR9","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41523-025-00785-0","volume":"11","author":"Y Qian","year":"2025","unstructured":"Qian Y, Jin N, Rao S, Wang Y, Li X, Pan W, et al. NR4A3 potentials M1-like macrophage polarization to facilitate anti-tumor immune responses in breast cancer. npj Breast Cancer. 2025;11:67. https:\/\/doi.org\/10.1038\/s41523-025-00785-0.","journal-title":"npj Breast Cancer"},{"key":"2307_CR10","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/j.it.2023.10.006","volume":"44","author":"G Katkar","year":"2023","unstructured":"Katkar G, Ghosh P. Macrophage states: there\u2019s a method in the madness. Trends Immunol. 2023;44:954\u201364. https:\/\/doi.org\/10.1016\/j.it.2023.10.006.","journal-title":"Trends Immunol"},{"key":"2307_CR11","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.molmed.2018.03.006","volume":"24","author":"JL Guerriero","year":"2018","unstructured":"Guerriero JL. Macrophages: the road less traveled, changing anticancer therapy. Trends Mol Med. 2018;24:472\u201389. https:\/\/doi.org\/10.1016\/j.molmed.2018.03.006.","journal-title":"Trends Mol Med"},{"key":"2307_CR12","doi-asserted-by":"publisher","first-page":"923481","DOI":"10.3389\/fimmu.2022.923481","volume":"13","author":"B Xu","year":"2022","unstructured":"Xu B, Sun H, Song X, Liu Q, Jin W. Mapping the tumor microenvironment in TNBC and deep exploration for M1 macrophages-associated prognostic genes. Front Immunol. 2022;13:923481. https:\/\/doi.org\/10.3389\/fimmu.2022.923481.","journal-title":"Front Immunol"},{"key":"2307_CR13","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/s41422-025-01107-6","volume":"35","author":"P Broz","year":"2025","unstructured":"Broz P. Pyroptosis: molecular mechanisms and roles in disease. Cell Res. 2025;35:334\u201344. https:\/\/doi.org\/10.1038\/s41422-025-01107-6.","journal-title":"Cell Res"},{"key":"2307_CR14","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12943-025-02344-4","volume":"24","author":"C Huang","year":"2025","unstructured":"Huang C, Li J, Wu R, Li Y, Zhang C. Targeting pyroptosis for cancer immunotherapy: mechanistic insights and clinical perspectives. Mol Cancer. 2025;24:131. https:\/\/doi.org\/10.1186\/s12943-025-02344-4.","journal-title":"Mol Cancer"},{"key":"2307_CR15","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.gendis.2022.11.023","volume":"11","author":"J Fan","year":"2024","unstructured":"Fan J, Zhang Z, Chen H, Chen D, Yuan W, Li J, et al. Zinc finger protein 831 promotes apoptosis and enhances chemosensitivity in breast cancer by acting as a novel transcriptional repressor targeting the STAT3\/Bcl2 signaling pathway. Genes Dis. 2024;11:430\u201348. https:\/\/doi.org\/10.1016\/j.gendis.2022.11.023.","journal-title":"Genes Dis"},{"key":"2307_CR16","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1186\/s13046-018-1002-1","volume":"37","author":"Y He","year":"2018","unstructured":"He Y, Jiang Z, Chen C, Wang X. Classification of triple-negative breast cancers based on immunogenomic profiling. J Exp Clin Cancer Res. 2018;37:327. https:\/\/doi.org\/10.1186\/s13046-018-1002-1.","journal-title":"J Exp Clin Cancer Res"},{"key":"2307_CR17","doi-asserted-by":"publisher","first-page":"600573","DOI":"10.3389\/fonc.2020.600573","volume":"10","author":"R Thomas","year":"2021","unstructured":"Thomas R, Al-Khadairi G, Decock J. Immune checkpoint inhibitors in triple negative breast cancer treatment: promising future prospects. Front Oncol. 2021;10:600573. https:\/\/doi.org\/10.3389\/fonc.2020.600573.","journal-title":"Front Oncol"},{"key":"2307_CR18","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","volume":"13","author":"G Bianchini","year":"2016","unstructured":"Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016;13:674\u201390. https:\/\/doi.org\/10.1038\/nrclinonc.2016.66.","journal-title":"Nat Rev Clin Oncol"},{"key":"2307_CR19","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s41392-021-00507-5","volume":"6","author":"P Yu","year":"2021","unstructured":"Yu P, Zhang X, Liu N, Tang L, Peng C, Chen X. Pyroptosis: mechanisms and diseases. Signal Transduct Target Ther. 2021;6:128. https:\/\/doi.org\/10.1038\/s41392-021-00507-5.","journal-title":"Signal Transduct Target Ther"},{"key":"2307_CR20","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1186\/s12943-024-02183-9","volume":"23","author":"H Wang","year":"2024","unstructured":"Wang H, Wang T, Yan S, Tang J, Zhang Y, Wang L, et al. Crosstalk of pyroptosis and cytokine in the tumor microenvironment: from mechanisms to clinical implication. Mol Cancer. 2024;23:268. https:\/\/doi.org\/10.1186\/s12943-024-02183-9.","journal-title":"Mol Cancer"},{"key":"2307_CR21","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/s41577-019-0127-6","volume":"19","author":"DG DeNardo","year":"2019","unstructured":"DeNardo DG, Ruffell B. Macrophages as regulators of tumour immunity and immunotherapy. Nat Rev Immunol. 2019;19:369\u201382. https:\/\/doi.org\/10.1038\/s41577-019-0127-6.","journal-title":"Nat Rev Immunol"},{"key":"2307_CR22","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/s41586-020-2071-9","volume":"579","author":"Z Zhang","year":"2020","unstructured":"Zhang Z, Zhang Y, Xia S, Kong Q, Li S, Liu X, et al. Gasdermin E suppresses tumour growth by activating anti-tumour immunity. Nature. 2020;579:415\u201320. https:\/\/doi.org\/10.1038\/s41586-020-2071-9.","journal-title":"Nature"},{"key":"2307_CR23","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.molcel.2023.11.040","volume":"84","author":"Y Ai","year":"2024","unstructured":"Ai Y, Meng Y, Yan B, Zhou Q, Wang X. The biochemical pathways of apoptotic, necroptotic, pyroptotic, and ferroptotic cell death. Mol Cell. 2024;84:170\u20139. https:\/\/doi.org\/10.1016\/j.molcel.2023.11.040.","journal-title":"Mol Cell"},{"key":"2307_CR24","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.3390\/ijms22042212","volume":"22","author":"J Soboci\u0144ska","year":"2021","unstructured":"Soboci\u0144ska J, Molenda S, Machnik M, Oleksiewicz U. KRAB-ZFP transcriptional regulators acting as oncogenes and tumor suppressors: an overview. Int J Mol Sci. 2021;22:2212. https:\/\/doi.org\/10.3390\/ijms22042212.","journal-title":"Int J Mol Sci"},{"key":"2307_CR25","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1242\/dev.132605","volume":"144","author":"G Ecco","year":"2017","unstructured":"Ecco G, Imbeault M, Trono D. KRAB zinc finger proteins. Development. 2017;144:2719\u201329. https:\/\/doi.org\/10.1242\/dev.132605.","journal-title":"Development"},{"key":"2307_CR26","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.tig.2023.08.003","volume":"39","author":"O Rosspopoff","year":"2023","unstructured":"Rosspopoff O, Trono D. Take a walk on the KRAB side. Trends Genet. 2023;39:844\u201357. https:\/\/doi.org\/10.1016\/j.tig.2023.08.003.","journal-title":"Trends Genet"},{"key":"2307_CR27","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.devcel.2011.12.001","volume":"22","author":"GL Sen","year":"2012","unstructured":"Sen GL, Boxer LD, Webster DE, Bussat RT, Qu K, Zarnegar BJ, et al. ZNF750 is a p63 target gene that induces KLF4 to drive terminal epidermal differentiation. Dev Cell. 2012;22:669\u201377. https:\/\/doi.org\/10.1016\/j.devcel.2011.12.001.","journal-title":"Dev Cell"},{"key":"2307_CR28","doi-asserted-by":"publisher","first-page":"9311","DOI":"10.1073\/pnas.1920880117","volume":"117","author":"RJ Weiss","year":"2020","unstructured":"Weiss RJ, Spahn PN, Toledo AG, Chiang AWT, Kellman BP, Li J, et al. ZNF263 is a transcriptional regulator of heparin and heparan sulfate biosynthesis. Proc Natl Acad Sci. 2020;117:9311\u20137. https:\/\/doi.org\/10.1073\/pnas.1920880117.","journal-title":"Proc Natl Acad Sci"},{"key":"2307_CR29","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.7150\/thno.94537","volume":"14","author":"C Zhang","year":"2024","unstructured":"Zhang C, Liu Y, Jiang J, Chen C, Duan Z, Su H, et al. Targeting tumor cell-to-macrophage communication by blocking vtn-C1qbp interaction inhibits tumor progression via enhancing macrophage phagocytosis. Theranostics. 2024;14:2757\u201376. https:\/\/doi.org\/10.7150\/thno.94537.","journal-title":"Theranostics"},{"key":"2307_CR30","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41420-024-01884-w","volume":"10","author":"H Konishi","year":"2024","unstructured":"Konishi H, Haga Y, Okumura M, Tsujino H, Higashisaka K, Tsutsumi Y. Coculture with macrophages alters ferroptosis susceptibility of triple-negative cancer cells. Cell Death Discovery. 2024;10:108. https:\/\/doi.org\/10.1038\/s41420-024-01884-w.","journal-title":"Cell Death Discovery"},{"key":"2307_CR31","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41590-022-01398-6","volume":"24","author":"S Ma","year":"2023","unstructured":"Ma S, Sun B, Duan S, Han J, Barr T, Zhang J, et al. YTHDF2 orchestrates tumor-associated macrophage reprogramming and controls antitumor immunity through CD8+\u2009T cells. Nat Immunol. 2023;24:255\u201366. https:\/\/doi.org\/10.1038\/s41590-022-01398-6.","journal-title":"Nat Immunol"},{"key":"2307_CR32","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1186\/s13046-025-03569-3","volume":"44","author":"K Lei","year":"2025","unstructured":"Lei K, Chen J, Deng Y, Peng Y, Zhai X, Ren X, et al. Cracking the code of cancer immunotherapy resistance: emerging roles of pyroptosis and necroptosis. J Exp Clin Cancer Res. 2025;44:308. https:\/\/doi.org\/10.1186\/s13046-025-03569-3.","journal-title":"J Exp Clin Cancer Res"},{"key":"2307_CR33","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s10549-021-06097-8","volume":"186","author":"EM Jiagge","year":"2021","unstructured":"Jiagge EM, Ulintz PJ, Wong S, McDermott SP, Fossi SI, Suhan TK, et al. Multiethnic PDX models predict a possible immune signature associated with TNBC of African ancestry. Breast Cancer Res Treat. 2021;186:391\u2013401. https:\/\/doi.org\/10.1007\/s10549-021-06097-8.","journal-title":"Breast Cancer Res Treat"},{"key":"2307_CR34","doi-asserted-by":"publisher","first-page":"4062","DOI":"10.1158\/0008-5472.CAN-24-5023","volume":"85","author":"AL Rinkenbaugh","year":"2025","unstructured":"Rinkenbaugh AL, Qi Y, Cai S, Shao J, Baameur Hancock F, Jeter-Jones SL, et al. An annotated biobank of triple-negative breast cancer patient-derived xenografts features treatment-na\u00efve and longitudinal samples during neoadjuvant chemotherapy. Cancer Res. 2025;85:4062\u201380. https:\/\/doi.org\/10.1158\/0008-5472.CAN-24-5023.","journal-title":"Cancer Res"},{"key":"2307_CR35","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","volume":"9","author":"B Wu","year":"2024","unstructured":"Wu B, Zhang B, Li B, Wu H, Jiang M. Cold and hot tumors: from molecular mechanisms to targeted therapy. Signal Transduct Target Ther. 2024;9:274. https:\/\/doi.org\/10.1038\/s41392-024-01979-x.","journal-title":"Signal Transduct Target Ther"},{"key":"2307_CR36","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/nrg.2016.93","volume":"17","author":"PA Jones","year":"2016","unstructured":"Jones PA, Issa J-PJ, Baylin S. Targeting the cancer epigenome for therapy. Nat Rev Genet. 2016;17:630\u201341. https:\/\/doi.org\/10.1038\/nrg.2016.93.","journal-title":"Nat Rev Genet"},{"key":"2307_CR37","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1124\/pharmrev.120.000171","volume":"73","author":"SE Corcoran","year":"2021","unstructured":"Corcoran SE, Halai R, Cooper MA. Pharmacological inhibition of the nod-like receptor family pyrin domain containing 3 inflammasome with MCC950. Pharmacol Rev. 2021;73:968\u20131000. https:\/\/doi.org\/10.1124\/pharmrev.120.000171.","journal-title":"Pharmacol Rev"},{"key":"2307_CR38","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.tips.2025.04.007","volume":"46","author":"JE Cabral","year":"2025","unstructured":"Cabral JE, Wu A, Zhou H, Pham MA, Lin S, McNulty R. Targeting the NLRP3 inflammasome for inflammatory disease therapy. Trends Pharmacol Sci. 2025;46:503\u201319. https:\/\/doi.org\/10.1016\/j.tips.2025.04.007.","journal-title":"Trends Pharmacol Sci"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-026-02307-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02307-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02307-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T01:02:16Z","timestamp":1784682136000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13058-026-02307-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,23]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2307"],"URL":"https:\/\/doi.org\/10.1186\/s13058-026-02307-7","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,23]]},"assertion":[{"value":"3 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures were approved by the Institutional Animal Care and Use Committee of Army Medical University (approval number: AMUWEC20224960). 4T1-luc cells (5\u2009\u00d7\u200910\n                      5\n                      ) were orthotopically transplanted into the fourth mammary fat pad of 6-week-old female BALB\/c mice (\n                      n\n                      \u2009=\u20095\/group). MCC950 (10\u00a0mg\/kg) or PBS was administered intratumorally every other day. Tumor volume was monitored every 3 days and calculated as (length \u00d7 width\u00b2)\/2; mice were euthanized on day 21 for tumor weight and downstream analyses. The maximum permitted tumor burden (maximum diameter) specified in the approved protocol was 15\u00a0mm, and this limit was not exceeded in any experiment. Humane endpoints and monitoring frequency followed the approved protocol.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"133"}}